Stay updated with the latest dna-repair news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on dna-repair topics.
A major Chinese clinical study on ovarian cancer has been published in CA: A Cancer Journal for Clinicians, one of the world's highest-impact medical journal, marking a first for a Chinese researcher-led gynecological cancer trial, researchers said in Beijing on Sunday. The phase III FZOCUS-1 study tested fluzoparib, a PARP inhibitor developed by Chinese pharmaceutical giant Hengrui Pharma. The trial evaluated the drug as a "maintenance" therapy, treatment given to prevent cancer recurrence aft ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.